This map shows the geographic impact of Y Toyonaga's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Y Toyonaga with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Y Toyonaga more than expected).
This network shows the impact of papers produced by Y Toyonaga. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Y Toyonaga. The network helps show where Y Toyonaga may publish in the future.
Co-authorship network of co-authors of Y Toyonaga
This figure shows the co-authorship network connecting the top 25 collaborators of Y Toyonaga.
A scholar is included among the top collaborators of Y Toyonaga based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Y Toyonaga. Y Toyonaga is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Toyonaga, Y, et al.. (1999). [Clinical and bacteriological evaluation of ceftriaxone (CTRX) dosed once daily in children with community-acquired pneumonia].. PubMed. 52(4). 322–32.1 indexed citations
9.
Toyonaga, Y, Takashi Ishihara, Tohru Tezuka, & H Nakamura. (1998). [Pharmacokinetic and clinical evaluation of tazobactam/piperacillin in the pediatric field].. PubMed. 51(5). 325–45.
Kobayashi, Hiroyuki, et al.. (1993). [Judgment criteria in clinical tests for antibacterial agents used in pediatrics].. PubMed. 46(5). 411–20.1 indexed citations
12.
Toyonaga, Y, et al.. (1992). [Bacteriological, pharmacokinetic and clinical studies of 5% and 10% granules of cefdinir in the pediatric field].. PubMed. 45(1). 48–73.1 indexed citations
13.
Toyonaga, Y, et al.. (1992). [Pharmacokinetic and clinical studies on panipenem/betamipron in the pediatric field].. PubMed. 45(3). 329–51.1 indexed citations
14.
Toyonaga, Y, et al.. (1985). [Experimental and clinical studies on BRL 25000 (clavulanic acid-amoxicillin) granules in the pediatric field].. PubMed. 38(2). 373–413.2 indexed citations
15.
Toyonaga, Y, et al.. (1984). [Fundamental and clinical evaluation on ceftriaxone in the pediatric field].. PubMed. 37(11). 2060–82.3 indexed citations
16.
Toyonaga, Y, et al.. (1983). [Experimental and clinical evaluation of cefpiramide in pediatrics].. PubMed. 36(8). 2207–27.1 indexed citations
17.
Toyonaga, Y, et al.. (1982). [Laboratory and clinical studies of 9,3"-diacetylmidecamycin in the pediatric field].. PubMed. 35(6). 1475–92.1 indexed citations
18.
Toyonaga, Y, et al.. (1981). [Basic and clinical studies on cefoxitin in pediatrics (author's transl)].. PubMed. 34(3). 257–78.1 indexed citations
19.
Toyonaga, Y, et al.. (1980). [Fundamental and clinical studies of cefuroxime in pediatric purulent meningitis (author's transl)].. PubMed. 33(12). 1277–84.2 indexed citations
20.
Toyonaga, Y. (1979). [A study of serum concentration in children administered by intravenous injection of cefazolin. II. Evaluation about speciality of serum concentration in mature babies and premature babies (author's transl)].. PubMed. 32(8). 786–94.1 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.